FDA Approves First Treatment for MCT8 Deficiency
- FDA: 31 events in the last 90 days
- Previous: earlier the same day · FDA intends to evaluate changes to the PMTA regulatory framework
What happened
The U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patient
Summary assembled by rule from the sources below
Why it's spreading
Sources
Filing
- FDA Approves First Treatment for MCT8 DeficiencyFDA Press Releases